


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0087  
Inventors: Recipon et al.  
Serial No.: 09/705,500  
Filing Date: November 3, 2000  
Examiner: K. Canella  
Group Art Unit: 1642

Title: A Novel Method of Diagnosing,  
Monitoring, Staging, Imaging and  
Treating Cancer

I, Nathan P. Letts, Registration No. 36,581, certify that this correspondence is being depositing with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents and Trademarks, Washington, D.C. 20231.

On this date, April 17, 2002

  
Nathan P. Letts, Registration No. 36,581

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the

GP 1642  
RECEIVED  
APR 23 2002  
TECH CENTER 1600/2900

#10



date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

( ) Certification in Accordance with §1.97(e) is set forth below; or

( ) The fee of \$180.00 as set forth in §1.17(p) is attached.

( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).

(**XX**) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

(**XX**) A copy of the of the PCT Search Report for PCT Application PCT/US00/30482 which corresponds to the subject US application 09/705,500 is included.

( ) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449


(modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. \_\_\_\_\_, filed , for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

(XX) Due to the large size of some references, only relevant portions have been submitted. The included portions are as follows: WO 98/45436 A2 (Pages 1-91, 536-537, 575-616); WO 00/55174 A1 (Pages 1-13, 54, 98-104, 185, 245-261, 276, 290-544, 608-612, Sequence Listing 1, SL 342-343, SL 1244-1245, International Search Report). Full text of abbreviated reference is available if requested.

(XX) Reference WO 00/16795 A1 is in a foreign language but is accompanied by English language counterpart EP 1121936 A1. Reference JP 0229880 A2 is in a foreign language therefore a Geneseq Report has been added to demonstrate relevance.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-0434. This form is submitted in duplicate.

Respectfully submitted,

  
Nathan P. Letts  
Registration No. 36,581

Date: April 17, 2002

DiaDexus, Inc.  
343 Oyster Point Blvd.  
South San Francisco, CA 94080  
(650) 246-6400